ReviewAdvances in wound care2012
Update on Keloid Management: Clinical and Basic Science Advances.
Review in Advances in wound care, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02521402 (Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery), which is not on this map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pilot Study to Evaluate Clinical Outcomes With the Use of Biovance, a Dehydrated Decellularized Human Amnion Membrane Allograft, Following Keloid Revision Surgery
Who cites it
16 citing papers in PubMed, 39 citations in OpenAlex.
- Anti-Fibrotic Properties of a Decellularized Extracellular Matrix Scaffold from Porcine Small Intestinal Submucosa in Normal Human and Keloid Fibroblasts.International journal of molecular sciences · 2025Article
- Article
- Pharmacotherapy for Keloids and Hypertrophic Scars.International journal of molecular sciences · 2024Review
- Deciphering the single-cell transcriptome network in keloids with intra-lesional injection of triamcinolone acetonide combined with 5-fluorouracil.Frontiers in immunology · 2023Article
- Activity of keloids evaluated by multimodal photoacoustic/ultrasonic imaging system.Photoacoustics · 2021Article
- Keloids: a review of therapeutic management.International journal of dermatology · 2021Review
- Emerging and Novel Therapies for Keloids: A compendious review.Sultan Qaboos University medical journal · 2021Review
- Histological Changes Related to Symptomatic Improvement of Spontaneous Keloids Treated with a Low-Dosage Regimen of UVA-1 Phototherapy.Dermatopathology (Basel, Switzerland) · 2020Article
- Biological approaches for hypertrophic scars.International wound journal · 2020Review
- Squamous cell carcinoma arising in a keloid scar.Medical journal, Armed Forces India · 2019Article
- Critical role of inflammatory mast cell in fibrosis: Potential therapeutic effect of IL-37.Cell proliferation · 2018Review
- Keloid risk in patients with atopic dermatitis: a nationwide retrospective cohort study in Taiwan.BMJ open · 2018Article
- The antifibrotic effect of isolate tagitinin C from tithonia diversifolia (Hemsley) A. Gray on keloid fibroblast cell.The Pan African medical journal · 2018Article
- Keloid Management: A Retrospective Case Review on a New Approach Using Surgical Excision, Platelet-Rich Plasma, and In-office Superficial Photon X-ray Radiation Therapy.Advances in skin & wound care · 2016Article
- Cutaneous basal cell carcinoma arising within a keloid scar: a case report.OncoTargets and therapy · 2016Article
- Promising Novel Treatment against Keloids: Antivascular Endothelial Growth Factor Agents.Journal of research in pharmacy practiceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundKeloids are benign, fibroproliferative lesions that represent abnormal healing resulting in excessive fibrosis. They are composed of mainly type III (early) or type I (late) collagen. Some of the symptoms include pruritus, tenderness, and pain. Often, they are very difficult to treat and prevent from recurrence. In contrast to hypertrophic scars, keloids extend beyond the margin of the wound. THE PROBLEM: There is very limited evidence on the best wound management for minimizing scarring. Multiple available therapeutic modalities have been used for the treatment of keloids; however, high-recurrence rates continue to be reported. Unsuccessful treatment of keloids leads to psychological impact on the patients and increased economic burden. BASIC/CLINICAL SCIENCE ADVANCES: Currently, there are biological and antineoplastic agents that can potentially treat and prevent excessive scar formation. Some of them have been used as "off label" therapies, and others are still in the experimental phase such as interferon alpha (IFN-α), imiquimod, and transforming growth factor beta1 (TGF-β1). The use of IFN-α2b showed 18% recurrence rate when applied to postsurgical excised keloids. Imiquimod 5% can lower recurrence rate on postshaved keloids to 37.5% at 6-month and to 0% at a 12-month follow-up period. TGF-β1 oligonucleotides have shown effective and long-lasting inhibition of TGF-β-mediated scarring
conclusionLatest discoveries in the use of novel agents suggest therapeutic alternatives for the prevention of recurrences of hypertrophic scars and postexcision keloid lesions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.